Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
mCRPC advances come with choices, challengesIn this article, Robert A. Dowling, MD, examines some of the practice-related implications of the rapid change in the management of patients with advanced prostate cancer.
Best of GU Cancers 2015: Dr. Thrasher’s picks and moreNew, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
No impact on PCa agent following bankruptcy filingDendreon Corp., the maker of sipuleucel-T (Provenge), said it expects no impact on access to the prostate cancer immunotherapy following the company’s Chapter 11 filing last week.
Approval of enzalutamide pre-chemo a ‘game changer’
Approval of enzalutamide pre-chemo a ‘game changer’The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
Best of AUA 2014: Prostate Cancer
Best of AUA 2014: Prostate CancerMichael C. Gong, MD, PhD, presents the take home messages on prostate cancer from the AUA annual meeting in Orlando, FL, including new findings about enzalutamide (XTANDI).
Advanced prostate cancer research focuses on newer agents for mCRPCResearch in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
Anti-androgen’s benefit in chemo-naïve men tops prostate cancer news
Anti-androgen’s benefit in chemo-naïve men tops prostate cancer newsThe androgen-receptor blocker enzalutamide (XTANDI) increases survival by 29% in men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of the disease by 81%, according to new phase III study results in men who had not previously received chemotherapy.
Collaboration urged for advanced prostate cancer careWith a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.
Sipuleucel-T viable during abiraterone treatmentData from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.